Showing 371-380 of 9526 results for "".
How to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.Key Components of an Effective Strategic Plan
https://practicaldermatology.com/topics/practice-management/key-components-of-an-effective-strategic-plan/23933/A number of actionable steps can effectively and efficiently ensure that your practice stays on track.10 Steps to Building Content That Gets Results For Your Practice in 2023
https://practicaldermatology.com/topics/practice-management/10-steps-to-building-content-that-gets-results-for-your-practice-in-2023/23846/Editorial calendars can help organize your marketing content for the year ahead.At Your Service: Championing Employee Leadership
https://practicaldermatology.com/topics/practice-management/at-your-service-championing-employee-leadership/23793/How to develop engaged staff members who perform at the owner level.Estrogen and Skin: What Can We Do
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/estrogen-and-skin-what-can-we-do/20123/There’s accumulated evidence that depletion of estrogen with age contributes to the visible signs of skin aging. But dermatologists haven’t had many treatment options—until now. Joel L. Cohen, MD addresses the latest developments in care for estrogen deficient skin.Top Tips for Increasing Social Media Engagement
https://practicaldermatology.com/topics/practice-management/top-tips-for-increasing-social-media-engagement/23709/It takes time to grow your base, but if you know your audience and strategize, you can see gains.DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyCosmetic Surgery Forum: 2021 Recap
https://practicaldermatology.com/topics/skin-cancer-photoprotection/cosmetic-surgery-forum-2021-recap/20032/Cosmetic Surgery Forum founder and director Joel Schlessinger, MD offers an overview of the 2021 conference in Nashville.Rethink How You Market Your Practice During the Holidays
https://practicaldermatology.com/topics/practice-management/rethink-how-you-market-your-practice-during-the-holidays/23607/Winter can be the “gift that keeps on giving”—if you know how to leverage the season.DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improves